SGLT2 inhibitor dapagliflozin attenuates HIV-associated cardiac fibrosis, steatosis and diastolic dysfunction in a mouse model via inhibition of TGFβ signaling

AIDS 2026 Open access

Read full text
Authors: J Zachariah Laurence, Kumar Subramani, Denys Babii, Benjamin Walker, Trevor Word, Jasimuddin Ahamed
DOI: 10.1097/qad.0000000000004464
Cited by: 1
References: 14

Abstract

Myocardial fibrosis, steatosis, and heart failure with preserved ejection fraction are increasing among people with HIV (PWH). The sodium-glucose cotransporter type 2 inhibitor (SGLT2i) dapagliflozin has efficacy for cardiovascular disease (CVD) prevention in type 2 diabetes and is a promising therapy for the inflammatory component of CVD risk in PWH. We show dapagliflozin preserved diastolic function and suppressed cardiac fibrosis and steatosis linked to HIV in mice, suggesting potential utility in PWH.

Fields of Study & Subjects

Diabetes Treatment and Management Cardiovascular Function and Risk Factors HIV-related health complications and treatments

Publication details

Journal / source
AIDS
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
40
Issue
6
Pages
863–865
Publication date
29 April 2026
Language
EN